Oxford Centre for Haematology

Training Opportunities

Nurses Training Evenings

OCH supports training evenings for nurses in all areas of haematology.

Annual Meeting

Information for Patients

Training Opportunities

Paresh Vyas

Professor of Haematology

paresh.vyas@imm.ox.ac.uk

The OCH Management Board has as members the Director of the OCH, the Head of Clinical Haematology, the Head of Laboratory Haematology, the Head of the Radcliffe Department of Medicine, the Head of the Nuffield Division of Clinical Laboratory Sciences, the Director of the MRC Molecular Haematology Unit, the Director of the MRC Human Immunology Unit, the RDM Research Strategy Coordinator and the Administrator of the OCH.

Latest publications

The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Journal article

Mapperley C. et al, (2021), J Exp Med, 218
Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial.
Journal article

Law ZK. et al, (2021), J Am Heart Assoc
To Bi or not to Bi: Acute Erythroid Leukemias and hematopoietic lineage choice.
Journal article

di Genua C. and Nerlov C., (2021), Exp Hematol
COVID-19 convalescent plasma: interim recommendations from the AABB.
Journal article

Cohn CS. et al, (2021), Transfusion
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Journal article

Estcourt L., (2021), New England Journal of Medicine

What's new

Blood red petri-dish in the hand of a researcher with bacterial colonies grown on the plate.

Understanding clonal haematopoiesis for COVID and cancer

30 September 2020

3d rendered medically accurate illustration of the human blood cells and lymphocytes

Developing a rapid and cost-effective way to identify newborns at risk of leukaemia

21 August 2020

MRC WIMM researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.

Acute erythroid leukemia commonly involves both myeloid and erythroid lineage transformation. Di Genua et al. show that combined Cebpa and Gata2 mutations induce bi-lineage AEL. The Gata2 mutation (bottom soil layer) increases chromatin accessibility of erythroid transcription factor motifs (red roots) and decreases chromatin accessibility of myeloid transcription factor motifs (blue roots) while bi-allelic Cebpa mutation (top soil layer) increases erythroid transcription factor expression. This transforms neutrophil-monocyte progenitors into bi-potent leukemia-initiating cells that produce both myeloid and erythroid blasts (red and blue flowers, respectively). Artwork by Rae Cook.

Nerlov and Vyas labs develop first pre-clinical model of rare leukaemia

26 May 2020

The collaboration has led to the first pre-clinical model of acute erythroid leukaemia.

Two MRC MHU researchers selected to participate in prestigious haematology training programme

21 January 2020

Congratulations to Dr Simona Valletta and Dr Sarah Gooding, who were selected for the Translational Research Training in Hematology Program, a year-long training and mentoring experience by the American Society of Hematology and the European Hematology Association.